Core Insights - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index has shown a positive trend, with notable increases in constituent stocks such as Yirui Technology (up 14.00%) and Microelectronic Physiology (up 11.01%) [1][3] - The Jiashi Sci-Tech Medicine ETF has experienced significant trading activity, with a turnover rate of 28.3% and a total transaction volume of 71.52 million yuan, indicating a vibrant market [3] Market Performance - As of August 15, 2025, the Jiashi Sci-Tech Medicine ETF has achieved a net value increase of 56.25% over the past year, with a maximum single-month return of 23.29% since its inception [3] - The top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index account for 49.14% of the index, with leading companies including United Imaging Healthcare and BeiGene [3][5] Policy and Industry Trends - Recent national regulations aim to enhance drug accessibility and reduce patient burdens, promoting the circulation of pharmaceuticals and releasing more policy dividends for the innovative drug market [5] - The pharmaceutical and chemical manufacturing sectors are undergoing significant policy reforms and global transformations, focusing on drug procurement optimization and supply chain security [6]